studies

breast cancer (BC), EGFR inhibitor vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsLUX-Breast 1, 2016 1.48 [1.12; 1.95] 1.48[1.12; 1.95]LUX-Breast 1, 201610%508NAnot evaluable progression or deaths (PFS)detailed resultsLUX-Breast 1, 2016 1.10 [0.86; 1.41] 1.10[0.86; 1.41]LUX-Breast 1, 201610%508NAnot evaluable objective responses (ORR)detailed resultsLUX-Breast 1, 2016 1.04 [0.71; 1.52] 1.04[0.71; 1.52]LUX-Breast 1, 201610%502NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-02 15:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974